• Publications
  • Influence
Cannabis as a substitute for prescription drugs – a cross-sectional study
Background The use of medical cannabis is increasing, most commonly for pain, anxiety and depression. Emerging data suggest that use and abuse of prescription drugs may be decreasing in states whereExpand
  • 89
  • 5
  • PDF
Sex Differences in Cannabis Use and Effects: A Cross-Sectional Survey of Cannabis Users
Abstract Introduction: Despite known sex differences in the endocannabinoid system of animals, little attention has been paid to sex differences in human's cannabis use patterns and effects. TheExpand
  • 85
  • 3
  • PDF
Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease
Background: Reduced glutathione (GSH) is an endogenously synthesized tripeptide depleted early in the course of Parkinson’s disease (PD) and GSH augmentation has been proposed as a therapeuticExpand
  • 27
  • 3
  • PDF
Coenzyme Q10 deficiency in patients with Parkinson's disease
UNLABELLED Reactive oxygen species (ROS) are well known to contribute to the pathophysiology of Parkinson's disease (PD). Clinical trials of antioxidants are currently underway in PD patients,Expand
  • 51
  • 2
Role of Diet and Nutritional Supplements in Parkinson's Disease Progression
Objectives The goal of this study is to describe modifiable lifestyle variables associated with reduced rate of Parkinson's disease (PD) progression. Methods The patient-reported outcomes in PDExpand
  • 40
  • 2
  • PDF
A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy
Abstract Background: The political climate around Cannabis as a medicine is rapidly changing. Legislators are adopting policies regarding appropriate medical applications, while the paucity ofExpand
  • 48
  • 2
  • PDF
A randomized, double‐blind phase I/IIa study of intranasal glutathione in Parkinson's disease
Depletion of reduced glutathione is associated with PD and glutathione augmentation has been proposed as a disease‐modifying strategy. The aim of this study was to determine the safety andExpand
  • 29
  • 2
Central nervous system uptake of intranasal glutathione in Parkinson’s disease
Glutathione (GSH) is depleted early in the course of Parkinson’s disease (PD), and deficiency has been shown to perpetuate oxidative stress, mitochondrial dysfunction, impaired autophagy, and cellExpand
  • 27
  • 1
Glutathione as a Biomarker in Parkinson's Disease: Associations with Aging and Disease Severity
Objectives. Oxidative stress contributes to Parkinson's disease (PD) pathophysiology and progression. The objective was to describe central and peripheral metabolites of redox metabolism and toExpand
  • 23
  • 1
  • PDF
Safety survey of intranasal glutathione.
PURPOSE Glutathione depletion has been documented in several disease states, and exogenous administration has been hypothesized to have therapeutic potential for some conditions. In an effort toExpand
  • 13
  • 1
...
1
2
3
...